PAVM PAVmed Inc.

CIK 0001624326 50 ready 8-Ks latest August 14, 2026, 10:44 AM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline

Ready 8-Ks 50

Latest filing August 14, 2026, 10:44 AM ET

Top materiality 0.90

Event mix other_material ×25 · earnings ×11 · regulatory ×8

Sentiment 9 pos · 9 neg · 32 neu

Latest earnings reported 2026-Q2

Executive change recent →

SHENANIGAN SCORE 3 / 7 see the board

Recent 8-K filings for PAVM

Highest-materiality recent filing

PAVmed exchanges $22.3M convertible notes for Series C Preferred Stock and enters separate $2.65M purchase

November 21, 2024, 6:59 PM ET debt materiality 0.90 negative item 1.01 item 3.02 item 3.03 item 9.01

Exchanged $22,347,543 principal amount of Senior Secured Convertible Notes for 22,347 shares of Series C Preferred Stock.
Series C Preferred Stock carries 7.875% annual dividend, convertible at $1.068 per share, and redeemable at 132.5% of stated value.

Read filing →

August 14, 2026, 10:44 AM ET earnings materiality 0.70 positive item 2.02 item 7.01 item 9.01

PAVmed Q2 2026 net loss $5.5M; Lucid EsoGuard revenue $1.5M, cash up to $3.8M

Q2 2026 GAAP net loss ~$5.5M ($0.87/diluted share); non-GAAP adjusted net loss ~$1.7M ($0.27/share).
May 15, 2026, 8:05 AM ET earnings materiality 0.70 neutral item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

PAVmed Q1 GAAP net loss $7.0M; Lucid Diagnostics revenue $1.3M, 3,177 tests

GAAP net loss $7.0M ($4.42 diluted EPS); non-GAAP adjusted loss $1.9M ($1.17 per share).
March 30, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases ×2

PAVmed completes $45M financing, eliminates convertible debt; Q4 net loss $1.8M

PAVmed completed $30M Series D preferred offering and $15M senior secured note, eliminating all outstanding convertible securities.
February 4, 2026, 6:59 PM ET other material materiality 0.80 positive item 1.01 item 1.02 item 2.03 item 3.02 item 3.03 item 5.03 item 7.01 item 9.01 ◈ Equity Issuances ×2◈ Material Agreements ×2

PAVmed closes $30M Series D Preferred and $15M Note, retires all convertible securities

Gross proceeds $30M from Series D Preferred; warrants exercisable for additional $30M upon positive Medicare LCD for EsoGuard.
December 30, 2025, 6:59 PM ET other material materiality 0.65 neutral item 3.03 item 5.03 item 7.01 item 2.02 item 9.01 ◈ Equity Issuances◈ Governance Changes

PAVmed announces 1-for-30 reverse stock split effective Jan 2, 2026 to regain Nasdaq compliance

1-for-30 reverse split effective Jan 2, 2026; authorized shares reduced from 250M to 25M.
December 5, 2025, 6:59 PM ET other material materiality 0.60 neutral item 5.07 item 9.01

PAVmed shareholders approve reverse stock split (1:10–1:30) and authorized share reduction to 25M

Stockholders approved reverse split (ratio 1:10–1:30, board to decide) and authorized share reduction from 250M to 25M.
November 13, 2025, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 7.01 item 9.01

PAVmed Q3 net loss $6.3M; Veris relaunches implant monitor; Lucid gets Medicare support

GAAP net loss $6.3M ($0.29 diluted EPS); non-GAAP adj loss $0.4M ($0.02) for Q3 2025.
September 11, 2025, 7:59 PM ET other material materiality 0.60 neutral item 8.01 item 9.01

PAVmed subsidiary Lucid Diagnostics closes $28.75M stock offering at $1.00/share

Lucid Diagnostics sold 28.75M shares at $1.00 each via underwritten offering.
August 14, 2025, 7:59 PM ET earnings materiality 0.65 negative item 2.02 item 7.01 item 9.01

PAVmed Q2 net loss $13.3M ($0.74/share); Lucid EsoGuard rev $1.2M on 2,756 tests

GAAP net loss $13.3M ($0.74 diluted EPS); non-GAAP adjusted loss $1.8M ($0.11/share).
July 30, 2025, 7:59 PM ET regulatory materiality 0.65 negative item 8.01 item 9.01

PAVmed receives Nasdaq extension to Jan 2026 to meet $1 minimum bid price

Company failed to regain compliance by initial July 22, 2025 deadline after Jan 23 notice.
May 15, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 7.01 item 9.01

PAVmed Q1 GAAP net income $17.7M, adjusted loss $0.9M; Lucid raises $30.6M, cash >$40M

GAAP net income attributable to common stockholders $17.7M ($0.34 diluted EPS); non-GAAP adjusted loss $0.9M ($0.07 per share).
April 17, 2025, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 9.01

PAVmed enters $2.88M at-the-market equity offering agreement with Maxim Group

ATM offering up to $2,880,000 of common stock under shelf registration effective April 15, 2025.
April 11, 2025, 7:59 PM ET other material materiality 0.75 neutral item 8.01 item 9.01

PAVmed subsidiary Lucid Diagnostics closes 14.4M share offering raising ~$16.1M net

Lucid Diagnostics closed sale of 14,375,000 shares at $1.20 each, including full exercise of underwriters' option.
March 25, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 7.01 item 9.01

PAVmed reports Q4 net income $1.3M; Lucid record tests, Veris financing, debt restructured

GAAP net income $1.3M ($0.12 diluted EPS); non-GAAP adjusted loss $0.7M ($0.06) per share.
February 21, 2025, 6:59 PM ET other material materiality 0.70 neutral item 3.02 item 9.01

PAVmed raises $2.37M via PIPE of common stock and pre-funded warrants with Veris subsidiary shares

Sale of 2,574,350 shares and 756,734 pre-funded warrants at $0.7115/unit; Veris issues 677,143 shares to investors.
January 24, 2025, 6:59 PM ET regulatory materiality 0.75 negative item 3.01 item 3.02 item 3.03 item 9.01 ◈ Listing & Compliance Notices ×2

PAVmed receives Nasdaq minimum bid price deficiency notice; sells Series C preferred shares

Nasdaq notice on Jan 23: common stock closing bid below $1 for 30 consecutive days; 180-day cure period until July 22, 2025.
January 21, 2025, 6:59 PM ET other material materiality 0.75 neutral item 3.01 item 3.02 item 3.03 item 5.03 item 8.01 item 9.01 ◈ Governance Changes

PAVmed exchanges $22.35M of convertible notes for Series C preferred; targets Nasdaq compliance

Exchanged $22,347,543 in principal plus interest of Senior Secured Convertible Notes for 22,347 Series C Preferred shares.
January 15, 2025, 6:59 PM ET other material materiality 0.65 negative item 5.03 item 5.07 item 9.01 ◈ Governance Changes

PAVmed stockholders approve 4x increase in authorized shares to 250M and Series C Preferred issuance

Stockholders approved amending the certificate of incorporation to increase authorized common shares from 50M to 250M, effective Jan 15, 2025.
November 29, 2024, 6:59 PM ET debt materiality 0.65 neutral item 1.01 item 2.03 item 3.03 item 9.01

PAVmed sub Lucid closes $21.95M convertible note placement; net $18.3M

Lucid Diagnostics (PAVmed sub) closed $21.95M in Senior Secured Convertible Notes to accredited investors.
November 21, 2024, 6:59 PM ET debt materiality 0.90 negative item 1.01 item 3.02 item 3.03 item 9.01

PAVmed exchanges $22.3M convertible notes for Series C Preferred Stock and enters separate $2.65M purchase

Exchanged $22,347,543 principal amount of Senior Secured Convertible Notes for 22,347 shares of Series C Preferred Stock.
November 14, 2024, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 7.01 item 9.01

PAVmed reports Q3 GAAP net income $64.3M driven by deconsolidation; Lucid EsoGuard revenue record $1.2M

Lucid Q3 EsoGuard revenue $1.2M, a record; 2,787 commercial tests; October single-month record >1,400 tests.
September 16, 2024, 7:59 PM ET other material materiality 0.85 negative item 2.01 item 5.02 item 3.01 item 7.01 item 9.01 ◈ executive_change ×3

PAVmed deconsolidates Lucid Diagnostics, expects ~$70M gain; faces Nasdaq delisting, appoints new director

Deconsolidated Lucid from financials; expects ~$70M non-cash gain in Q3 2024.
August 13, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 7.01 item 9.01

PAVmed Q2 GAAP net loss $10.9M; Lucid EsoGuard test volume record 3,147 (up 31% QoQ)

Q2 revenue $1.0M from EsoGuard test; GAAP net loss attributable to common $10.9M ($1.19/sh).
May 14, 2024, 7:59 PM ET earnings materiality 0.70 negative item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

PAVmed reports Q1 2024 net loss of $22.8M; EsoGuard revenue flat QoQ at $1.0M

GAAP net loss $22.8M ($2.62 per share); non-GAAP adjusted loss $8.6M ($0.99 per share).
May 7, 2024, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 3.03 item 3.02 item 5.03 item 9.01 ◈ Material Agreements

PAVmed subsidiary Lucid Diagnostics raises $11.6M in Series B-1 preferred stock offering

Lucid Diagnostics, PAVmed's majority-owned subsidiary, raised ~$11.6M via Series B-1 Convertible Preferred Stock.
May 1, 2024, 7:59 PM ET other material materiality 0.60 positive item 7.01 item 9.01

PAVmed subsidiary Veris Health signs MOU with Ohio State cancer center for pilot of Veris Cancer Care Platform

Veris and OSUCCC-James signed MOU to pilot the Veris Cancer Care Platform for cancer patients.
March 14, 2024, 7:59 PM ET debt materiality 0.65 neutral item 1.01 item 3.03 item 9.01 ◈ Material Agreements

PAVmed extends senior secured note maturities to 2025; pays $2M for covenant waiver

April 2022 Note maturity extended to April 4, 2025; September 2022 Note to September 8, 2025.
March 14, 2024, 7:59 PM ET other material materiality 0.60 neutral item 1.01 item 3.03 item 3.02 item 9.01 ◈ Material Agreements ×3

PAVmed subsidiary Lucid Diagnostics raises $12.5M via Series B Preferred Stock offering and exchange

Lucid Diagnostics sold 12,495 shares of Series B Convertible Preferred at $1,000/share, raising $12.495M.
March 8, 2024, 6:59 PM ET regulatory materiality 0.75 negative item 3.01 item 9.01 ◈ Listing & Compliance Notices

PAVmed receives Nasdaq delisting notice for MVLS below $35M minimum

Nasdaq notified PAVmed on March 7, 2024 that MVLS was below $35M for 30 consecutive days through March 6.
February 16, 2024, 6:59 PM ET other material materiality 0.65 neutral item 2.01 item 8.01 item 3.03 item 9.01

PAVmed distributes 3.33M Lucid Diagnostics shares as special dividend; warrant price adjusted

PAVmed distributed 3,331,747 shares of Lucid Diagnostics common stock as a special pro rata dividend to common and preferred stockholders.
February 9, 2024, 6:59 PM ET dividend materiality 0.75 positive item 8.01 item 9.01

PAVmed to distribute 3.3M Lucid Diagnostics shares (0.377/share) as special dividend Feb 15

Approximately 3,331,771 shares of Lucid Diagnostics (LUCD) distributed as special dividend to PAVmed stockholders.
January 8, 2024, 6:59 PM ET regulatory materiality 0.60 positive item 8.01 item 9.01

PAVmed regains Nasdaq minimum bid price compliance after bid price recovered above $1

Nasdaq notified PAVmed on Jan 5, 2024 that it regained compliance with Rule 5550(a)(2).
December 5, 2023, 6:59 PM ET other material materiality 0.70 neutral item 3.03 item 5.03 item 7.01 item 9.01 ◈ Governance Changes

PAVmed 1-for-15 reverse split Dec 7; declares Lucid dividend of ~3.3M shares

Reverse split at 1-for-15 effective Dec 7, 2023; authorized common reduced from 250M to 50M shares.
November 15, 2023, 6:59 PM ET earnings materiality 0.65 neutral item 2.02 item 7.01 item 9.01

PAVmed Q3 revenue $0.8M, net loss $0.16/share; Lucid revenue surges 392% sequentially

Q3 2023 revenue $0.8M; GAAP net loss $17.7M ($0.16 per share), non-GAAP adjusted loss $9.7M ($0.09).
June 28, 2023, 7:59 PM ET regulatory materiality 0.65 negative item 8.01 item 9.01

PAVmed receives additional 180-day Nasdaq extension to meet $1 bid price rule

Nasdaq granted PAVmed until December 26, 2023 to regain $1 minimum bid price compliance.
June 6, 2023, 7:59 PM ET other material materiality 0.60 neutral item 3.02 item 9.01

PAVmed issues 1.5M shares to Sunrise Labs for $750k development payment

1,500,000 common shares issued to Sunrise Labs as $750k advance for Veris Health monitor electronics.
April 3, 2023, 7:59 PM ET regulatory materiality 0.70 positive item 7.01 item 9.01

PAVmed Subsidiary Lucid Diagnostics Announces Medicare Coverage Determination for Esophageal Cancer Testing

MolDX Program published Future Effective Local Coverage Determination L39256 on March 30, 2023

Executive changes

Departed

James L. Cox, M.D.

Director

PAVM · PAVmed Inc.

Effective: 2024-09-10
Filed: September 16, 2024, 7:59 PM ET

James L. Cox, M.D., and Joan B. Harvey resigned from the Company’s board of directors.

Appointed

Sundeep Agrawal, M.D.

Class B Director

PAVM · PAVmed Inc.

Effective: 2024-09-10
Filed: September 16, 2024, 7:59 PM ET

the Company’s board of directors appointed Sundeep Agrawal, M.D. as a Class B director.

Departed

Joan B. Harvey

Director

PAVM · PAVmed Inc.

Effective: 2024-09-10
Filed: September 16, 2024, 7:59 PM ET

James L. Cox, M.D., and Joan B. Harvey resigned from the Company’s board of directors.

Appointed

Shaun O’Neil

Chief Operating Officer

PAVM · PAVmed Inc.

Effective: 2022-02-22
Filed: February 24, 2022, 6:59 PM ET

On February 22, 2022, the board of directors (the “Board”) of PAVmed Inc. (the “Company”) appointed Shaun O’Neil as the Company’s Chief Operating Officer.

Appointed

Joan B. Harvey

Class C director

PAVM · PAVmed Inc.

Effective: 2022-02-11
Filed: February 15, 2022, 6:59 PM ET

Effective February 11, 2022, the board of directors of PAVmed Inc. (the “ Company ”) appointed Joan B. Harvey as a Class C director of the Company.

Earnings & guidance

2026-Q2 EPS reported -$3.17 filing →

Materiality & sentiment trend

Max materiality 0.90 · Median 0.65 · Most common event other_material

9 positive 9 negative 32 neutral

source · PAVM on sec.gov